IRCT20210519051345N7 IRCT 2021-11-27 Tabriz University of Medical Sciences Bioequivalence study of Amantadine 100 mg capsule In vivo bioequivalence study if Amantadine 100 mg capsule manufactured by Fatak shimi Co. in comparison to innovator product Symmetetrel 2021-11-21 anticipated 24 Complete https://irct.ir/trial/59042 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: "Random number table" will be used. Each volunteer will be assigned a two-digit number. After making the table, we need randomly point to a spot on the table and select the numbers, Blinding description: In this study, Volunteers participating will be blinded to the type of product they are taking in each period (test or reference product). This means that the product will be given to the volunteers for administration outside the original packaging. Bioequivalence In the present study, no diseases will be examined and products will be administered by healthy volunteers. Intervention 1: Intervention group will receive one test drug product. Blood samples will be taken from the volunteers for 72 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be measured by liquid chromatography with mass spectroscopy detector. Intervention 2: Control group will receive one reference drug product. Blood samples will be taken from the volunteers for 72 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be measured by liquid chromatography with mass spectroscopy detector. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information.